Diagnosis and treatment of gastrointestinal dysfunction in hereditary TTR amyloidosis
- PMID: 31452022
- PMCID: PMC6763516
- DOI: 10.1007/s10286-019-00628-6
Diagnosis and treatment of gastrointestinal dysfunction in hereditary TTR amyloidosis
Abstract
Purpose: To review the management of gastrointestinal symptoms in patients with hereditary transthyretin amyloidosis, discussing diagnostic evaluations, assessment of disease progression and therapeutic strategies that could be implemented in routine practice.
Methods: Literature review. Key search terms included "gastrointestinal symptoms", "autonomic neuropathy", "hereditary transthyretin amyloidosis" and "familial amyloid polyneuropathy".
Results: Gastrointestinal disturbances are a common and serious manifestation of hereditary transthyretin amyloidosis, with significant effects on patients' quality of life and demonstrating a strong association with mortality. Gastrointestinal involvement is more often subclinical in the early stages of the disease, although in some patients gastric and/or bowel abnormalities may be the inaugural symptoms. In both cases, under-recognition, delayed investigation and suboptimal treatment frequently occur. A clear understanding of the mechanisms underlying gastrointestinal dysfunction in hereditary transthyretin amyloidosis is still lacking, but similar to diabetic enteropathy, multiple pathophysiological alterations seem to play a role.
Conclusions: Early detection and treatment of gastrointestinal disturbances is key to the successful treatment of this devastating disease. Gastroenterologists play a valuable role in both the diagnosis and the timely management of gastrointestinal symptoms in hereditary transthyretin amyloidosis and should, therefore, be part of a multidisciplinary and comprehensive approach to this disorder.
Keywords: Amyloidosis; Diarrhoea; Gastroparesis; Malabsorption; Transthyretin.
Conflict of interest statement
Dr. Obici declares speaker and consultation honoraria from Pfizer, Alnylam and Akcea. Dr. Suhr declares speaker and consultation honoraria from Pfizer, Alnylam, Akcea and Intellia.
References
-
- Wixner J, Tornblom H, Karling P, Anan I, Lindberg G. Abnormal small bowel motility in patients with hereditary transthyretin amyloidosis. Neurogastroenterol Motil. 2018;30(9):e13354. - PubMed
-
- Wixner J, Suhr OB, Anan I. Management of gastrointestinal complications in hereditary transthyretin amyloidosis: a single-center experience over 40 years. Expert Rev Gastroenterol Hepatol. 2018;12(1):73–81. - PubMed
Publication types
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
